Negative symptoms and cerebral imaging

L'Encéphale
A KaladjianJ-M Azorin

Abstract

A number of neuroanatomical and neurofonctional abnormalities have been evidenced by cerebral imaging studies in patients suffering from schizophrenia. Nevertheless, those specifically associated with the negative symptoms of this disease are still insufficiently known. This work is a review of selected studies that have assessed the brain correlates of negative symptoms in schizophrenia. Approaches using structural imaging have highlighted reduction of gray matter density or cortical thickness associated with negative symptoms, which is rather sparsely distributed within the frontal and temporal regions, localized nevertheless more particularly in the frontal medial and orbitofrontal areas, as well as the amygdalo-hippocampic complex. These deficits are concurrent with a loss of integrity of the principal paths of white matter tracts between frontal and limbic regions. On the other hand, neurofonctional abnormalities associated with negative symptoms involve especially the frontal areas and limbic striatum. A disturbed functioning within the fronto-striatal loops, related to a striatal dopaminergic deficit, may represent a potential explanatory hypothesis of the negative symptoms of schizophrenia, as suggested by studies using...Continue Reading

References

Feb 1, 1992·The British Journal of Psychiatry : the Journal of Mental Science·P F LiddleR S Frackowiak
May 1, 1988·The American Journal of Psychiatry·W T CarpenterA M Wagman
May 3, 2002·The American Journal of Psychiatry·Per KarlssonGöran Sedvall
Feb 20, 2004·The International Journal of Neuropsychopharmacology·Anissa Abi-Dargham
May 1, 2004·Psychopharmacology·Patricia S Goldman-RakicGraham V Williams
Jun 15, 2005·Schizophrenia Bulletin·Alex S Cohen, Nancy M Docherty
Sep 6, 2005·NeuroImage·Georg JuckelAndreas Heinz
Dec 7, 2005·The American Journal of Psychiatry·Robyn HoneaClare E Mackay
Dec 5, 2008·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Laura M RowlandRobert W Buchanan
Jan 9, 2009·Schizophrenia Research·Ian Ellison-Wright, Ed Bullmore
Aug 5, 2009·Archives of General Psychiatry·Michael J MinzenbergDavid C Glahn
Apr 7, 2010·The Journal of Clinical Psychiatry·Jozarni J Dlabac-de LangeAndré Aleman
May 11, 2010·Schizophrenia Research·Nicola G CascellaDavid J Schretlen
Jul 8, 2011·Psychological Medicine·S EhrlichD J Holt
Feb 18, 2012·Schizophrenia Research·Bernard A FischerRobert W Buchanan
Mar 8, 2013·JAMA Psychiatry·Aristotle N VoineskosBenoit H Mulsant
Jul 19, 2015·Schizophrenia Research·Jozarni J Dlabac-de LangeAndré Aleman

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.